Interventional neuropediatrics: Treatment of dystonic and spastic muscular hyperactivity with botulinum toxin A

Therapeutic effect of botulinum toxin A was studied in a group of pediatric patients (n=28) aged between 6 months and 18 years. The patients were diagnosed with cervical dystonia (n=6), adductor spasm of the hip (n=8), spastic drop foot (n=7) and various other focal motor problems associated with spastic muscular hyperactivity (n=7). The mean dose of botulinum toxin A (Dysport((R))) used to inject into the affected muscle was 22 U/kg body weight. Reduced muscular hyperactivity with a significant increase in joint mobility was achieved for dystonic (p<0.0001) as well as for spastic conditions in patients with adductor spasm (p<0.0002). For these patients the improved joint mobility represented a significant benefit for both daily activities and nursing care. Local paresis and local hematoma were observed in 1/28 and 1/28 patients, respectively; 1/28 patients developed a secondary non-response. However, apart from these side effects, no other adverse reactions to botulinum toxin A treatment were recorded during the treatment and observation period (12-64 months). Our results suggest that botulinum toxin A represents an effective and safe therapeutic substance for the treatment of pediatric patients suffering of focal motor problems due to dystonic or spastic muscular hyperactivity.